Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B‐non‐Hodgkin's lymphoma‐Berlin‐Frankfurt‐Münster‐90 protocol

Sun, Xiao Fei; Zhen, Zi Jun; Lui, Dong Gen; Yi, Xin; He, Yi; Wang, Zhi Hui; Lin, Jia Yu; Guan, Zhong

doi:10.1111/j.1600-0609.2006.00735.x

Cited by 15 publications

(14 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 At present, 80-90% of children with NHL are cured with intensive risk-adapted chemotherapy in the developed countries. 26 Malignant bone tumors constitute approximately 6% of all childhood malignancies, osteosarcoma (54%) is the most common among them in children under 20 years of age. 25 Osteosarcoma (OS) is a pleomorphic malignant tumor of bone in which the proliferating spindle cells produce osteoid or immature bone.…”

Section: Resultsmentioning

confidence: 99%

High Dose Methotrexate and Leucovorin Rescue Therapy in Childhood Malignancies: Experience in Resource-Limited Country

Ferdousi

Akhter

Nahar

et al. 2017

Bangladesh J Child Health

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

High Dose Methotrexate and Leucovorin Rescue Therapy in Childhood Malignancies: Experience in Resource-Limited Country

Ferdousi

Akhter

Nahar

et al. 2017

Bangladesh J Child Health

View full text Add to dashboard Cite

“…For example, in some parts of Central America, survival from acute lymphoblastic leukemia has reached 70% . Similar advances have been attained in the treatment of Wilms’ tumor, Hodgkin lymphoma, and Burkitt lymphoma in a variety of LMIC . Successful treatment of cancer in childhood in LMIC may be attributed to a variety of factors that include the establishment of twinning programs and implementation of adapted treatment regimens .…”

Section: Introductionmentioning

confidence: 93%

A Framework for Adapted Nutritional Therapy for Children With Cancer in Low- and Middle-Income Countries: A Report From the SIOP PODC Nutrition Working Group

Ladas

Arora

Howard

et al. 2016

Pediatr Blood Cancer

View full text Add to dashboard Cite

The utilization of adapted regimens for the treatment of pediatric malignancies has greatly improved clinical outcomes for children receiving treatment in low‐ and middle‐income countries (LMIC). Nutritional depletion has been associated with poorer outcomes, increased abandonment of therapy, and treatment‐related toxicities. Surveys have found that nutritional intervention is not incorporated routinely into supportive care regimens. Establishing nutritional programs based upon institutional resources may facilitate the incorporation of nutritional therapy into clinical care in a way that is feasible in all settings. We present a framework for establishing and monitoring of nutritional care based on the infrastructure of institutions in LMIC.

show abstract

“…CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOPlike regimens were the most frequently administrated first-line chemotherapy in 19 patients. Other regimens included EPOCH (etoposide, prednisone, vincristine, doxorubicin, and cyclophosphamide), COP (cyclophosphamide, vincristine, and prednisone), and the NHLBerlin-Frankfurt-Münster [BFM]-90 protocol [12]. The patient with Hodgkin lymphoma received BEACOPP (bleomycin, etoposide, doxorubicin; cyclophosphamide, vincristine, procarbazine, and prednisone) as first-line chemotherapy.…”

Section: Treatment Modalities and Response To Treatmentmentioning

confidence: 99%

Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients

et al. 2010

Self Cite

View full text Add to dashboard Cite

Primary lymphoma of bone (PLB) is a very rare neoplasm. Many aspects of this entity have not been well defined or reported in Chinese population. The purpose of our study is to identify the prognostic factors of PLB. Twenty-five patients newly diagnosed with PLB were included in this retrospective study. The main pathologic subtype of PLB was diffuse large B-cell lymphoma (DLBCL), followed by anaplastic large-cell lymphoma. The pelvis was the most commonly involved site (13 cases, 52%). The 5-year overall survival (OS) rate was 55.0%. Cox regression analysis demonstrated that IPI score was an independent prognostic factor of survival (RR = 8.46, P = 0.013). The mean survival time (MST) was 90.3 months for patients with radiation and 54.0 months for those without radiotherapy (P = 0.033). Patients who received the anti-CD20 monoclonal antibody rituximab therapy showed a favorable survival trend, but not significant benefit (MST: 74.5 months vs. 68.6 months, P = 0.149). Some clinical characteristics in the Chinese population are different from those in westerners. The frequency of T-cell subtypes is higher, and the pelvis is the most commonly involved site. Irradiation plus chemotherapy may be better than chemotherapy alone. The role of bisphosphonates and rituximab in PLB therapy warrants further investigation.

show abstract

Improved treatment outcome in Chinese children and adolescents with Burkitt's lymphoma and large cell lymphoma by using the modified B‐non‐Hodgkin's lymphoma‐Berlin‐Frankfurt‐Münster‐90 protocol

Abstract: This modified NHL-BFM-90 protocol is very effective for Chinese children and adolescents with BKL and large cell lymphomas, and represented an increase in the cure rates in childhood NHL in China.

Cited by 15 publications

References 17 publications

High Dose Methotrexate and Leucovorin Rescue Therapy in Childhood Malignancies: Experience in Resource-Limited Country

High Dose Methotrexate and Leucovorin Rescue Therapy in Childhood Malignancies: Experience in Resource-Limited Country

A Framework for Adapted Nutritional Therapy for Children With Cancer in Low- and Middle-Income Countries: A Report From the SIOP PODC Nutrition Working Group

Clinical characterization and prognostic factors of primary lymphoma of bone in case of Chinese patients

Contact Info

Product

Resources

About